Marilia Barreca

Here below are the publications (1) participated by Marilia Barreca along with Andrea Rinaldi (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).

Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

eJHaem, 27 luglio 2022

Facts & figures

Marilia Barreca has coordinated or participated in 5 publications
(as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) whose subjects can be represented by this 12 elements tag cloud:

antimitotic agents (1) ATR (1) BET (1) CDKN2A (1) DDR (1) HDAC (1) JAK (1) LRRK2 (1) lymphoma (1) LYMPHOMAS (1) malignant cell (1) PI3K (1)

Marilia Barreca has coordinated or participated in 5 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) featured by 5 scientific journals:

British Journal of Haematology (1) eJHaem (1) Journal of Medicinal Chemistry (1) Marine Drugs (1) Pharmacology and Therapeutics (1)

Marilia Barreca has coordinated or participated in 5 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) involving also 17 co-authors being active in Ticino:

Francesco Bertoni (5) Anastasios Stathis (3) Eugenio Gaudio (3) Filippo Spriano (3) Michele Mascia (2) Gaetanina Golino (2) Chiara Tarantelli (2) Alberto Jesus Arribas (2) Luciano Cascione (2) Giulio Sartori (2) Emanuele Zucca (2) Adele Ferragamo (1) Lorenzo Scalise (1) Giuseppe Perale (1) Luca Licenziato (1) Sara Napoli (1) Andrea Rinaldi (1)

Marilia Barreca has coordinated or participated in 5 pubblications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) in whose synopsis the 23 most frequently used terms (excluding 34 not relevant terms) are here listed:

M.B. WORD CLOUD overview (2) lymphoma (2) anti-tubulin (1) marine (1) anticancer (1) chemical (1) pyrrolo (1) cyclohepta (1) oxazoles (1) antimitotic (1) malignant (1) pharmacologic (1) screen (1) combinations (1) bet (1) lrrk (1) atr (1) elimusertib (1) exhibits (1) anti-lymphoma (1) synergizes (1) pi (1) copanlisib (1)

In the synopsis of the whole 3332 pubblications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations), the 197 most frequently used terms (excluding 34 not relevant or unfrequently used terms (terms used less than 10 times) are here listed:

THE WHOLE WORD CLOUD cancer (299) covid- (186) thyroid (111) pet (109) cardiac (107) prostate (107) sars-cov- (103) hiv (89) atrial (81) breast (81) coronary (79) sclerosis (76) fibrillation (69) lymphoma (68) pandemic (67) bone (54) aortic (52) heart (51) artery (51) stroke (50) liver (47) carcinoma (46) brain (44) antibodies (42) cardiovascular (41) lung (40) mri (39) transcatheter (36) metastatic (35) dna (35) ventricular (35) kidney (34) nodules (34) tumor (33) extracellular (33) virus (33) myocardial (32) knee (31) ultrasound (30) oncology (30) mitral (27) antibody (27) esmo (27) percutaneous (26) f-fdg (26) hepatitis (25) vesicles (25) spinal (25) antiplatelet (24) cervical (24) ischemic (24) osteoarthritis (23) tuberculosis (23) diabetes (23) infarction (23) chemotherapy (23) ovarian (22) sentinel (22) radiotherapy (22) bladder (22) pulmonary (22) sperm (22) ehra (22) endovascular (21) implantation (21) transplantation (21) vaccination (21) renal (21) blood (20) lymph (19) resonance (19) plasma (19) tomography (19) urinary (19) bacterial (19) b-cell (18) monoclonal (18) nuclear (18) tumors (18) pacing (18) fdg (17) colorectal (17) laparoscopic (17) mice (17) implantable (16) autoimmune (16) vaccine (16) transplant (16) coronavirus (16) immunodeficiency (16) radiomics (15) membrane (15) preclinical (15) metabolic (15) metabolism (15) vascular (15) musculoskeletal (15) tricuspid (14) endometrial (14) pneumonia (14) antiretroviral (14) biomarker (14) serum (14) mrna (14) metastasis (14) lymphomas (14) fractures (14) peripheral (14) neurocognitive (14) leukemia (14) occlusion (13) male (13) behavior (13) muscle (13) interventions (13) legs (13) radiation (13) arterial (13) hemorrhage (13) nerve (13) biomarkers (13) pregnancy (13) lymphocytic (13) medullary (12) malignant (12) platelet-rich (12) hiv- (12) metastases (12) tau (12) iga (12) conference (12) mutations (12) malignancy (12) brugada (12) joint (12) fna (12) grafts (12) ischemia (12) dementia (12) esc (12) radiology (11) baseline (11) gastric (11) intravenous (11) arrhythmia (11) dynamic (11) incontinence (11) burden (11) pi (11) contemporary (11) contrast-enhanced (11) pathways (11) adherence (11) catheter (11) parkinson (11) limb (11) cytology (11) signaling (11) neck (11) mesenchymal (11) senescence (11) lockdown (11) il- (11) administration (10) overview (10) regurgitation (10) depression (10) art (10) idiopathic (10) clonal (10) bayesian (10) checkpoint (10) antithrombotic (10) precision (10) recovery (10) possible (10) prognosis (10) cancers (10) vascularized (10) adapted (10) peptide (10) ecg (10) infectious (10) fixation (10) prolapse (10) pci (10) hip (10) migraine (10) skin (10) prophylaxis (10) follicular (10) igg (10) vitamin (10) epidemiology (10) lipid (10) refractory (10) anesthesia (10)

Il mondo delle startup

Marilia Barreca has participated - as a whole - in 5 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) - here below are the ones participated along with Andrea Rinaldi

1) Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

Marilia Barreca has participated - as a whole - in 5 publications
(as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) - here below are the ones participated along with Andrea Rinaldi